Brokers upgrading their price targets bodes well for the share price. Hard to value biotechs because they usually trade on high PEs. Also have to factor in their potential and their pipeline. It usually take years and years to commercialise a drug and also worth noting if other bios are targeting the same disease in the space. But regardless, the need for funding is mostly mitigated from the royalties from Arcadia. They can move faster with more money.
Brokers upgrading their price targets bodes well for the share...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |